AWARDED EUROPEAN GRANTS
- SINPAIN: A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis.
- REASON: Regenerating the diabetic heart and kidney by using stress-specific thyroid hormone nanocarriers
- SBR: Smart Bone Regeneration - Novel Regeneration Techniques for Large Bone Defects
- cmRNAbone: 3D Printed-Matrix Assisted Chemically Modified RNAs Bone Regenerative Therapy for Trauma and Osteoporotic Patients - A novel Gene Therapy for Bone Regeneration
- LIQD-CORNEA: A liquid corneal glue-filler as an alternative to transplantation in high-risk patients. EuroNanoMed III
- MODIFY-NK: A novel modified natural killer (NK) cell immunotherapy for the treatment of solid tumours. Eurostars.
- UNIVAX: A "Universal" Influenza Vaccine through Synthetic, Dendritic Cell-Targeted, Self-Replicating RNA Vaccines. FP-7 (HEALTH-F3-2013-601738)
- GAMBA: Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis. FP7 (NMP3-SL-2010-245993)
- CLINIGENE: European Network for the advancement of Clinical Gene Transfer & Therapy. FP6 (LSHB-CT-2006-018933)
- EPICURE: Functional genomics and neurobiology of epilepsy: a basis for new therapeutic strategies. FP6 (LSHM-CT-2006-037315)
- MAGSELECTOFECTION: Combined isolation and stable non-viral transfection of hematopoietic cells – a novel platform technology for ex vivo hematopoietic stem cell gene therapy. FP6 (LSHB-CT-2006-019038)
- IMPROVED PRECISION: Improved precision of nucleic acid based therapy of cystic fibrosis. FP6 (LSHB-CT-2004-005213)
Marie Skłodowska-Curie Actions - MSCA
- OcuTher: Educational Network in Ocular Drug Delivery and Therapeutics - This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 722717.
- NANOMED: “Nanomedicine: an integrative approach”. MARIE SKŁODOWSKA-CURIE ACTIONS HEALTH, H2020-MSCA-ITN-2015.
SCIENTIFIC PARTNER
- Cordis-Europa
- Europe
- INSERM
- CNRS
- INMED
- INRAE
- Technical University of Munchen (TUM)
- University of California, San Diego (UCSD)
- University of California, San Francisco (UCSF)
- The Scripps Research Institute
- Sanford-Burnham Medical Research Institute
BUSINESS & FINANCIAL PARTNERS
INSTITUTIONAL PARTNERS
CIR AGREEMENT
|
Oz Biosciences has obtained the Crédit d’Impôt Recherche (CIR) Agreement by the French Ministry of Higher Education, Research, and Innovation. This official accreditation enables French companies looking to collaborate with us on a biology R&D project (drug delivery, mRNAs, LNPs,...) to benefit from this accreditation and receive tax advantages. Contact us to explore how we can collaborate on your next R&D project! |
|
